LX-7101

DB16009InvestigationalSmall molecule

LX-7101 is under investigation in clinical trial NCT01528111 (Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension).

Mechanism: Pharmacologically active on LIM domain kinase 1 and LIM domain kinase 2
Curator reviewed
Formula / weight: C₂₃H₂₉N₇O₃ · 451.531 g/mol (avg)
Code names: HY-12659 · LX-7101

Resolves to

Compound

UNII74B3C4ZT96CAS1192189-69-7ChEMBLCHEMBL3356433

Structure

InChIKeyPWPNYABQEOGNNC-UHFFFAOYSA-NSMILESCN(C)C(=O)OC1=CC(NC(=O)C2(CN)CCN(CC2)C2=C3C(C)=CNC3=NC=N2)=CC=C1

Targets

P53667LIMK1P53671LIMK2O75116ROCK2

What you can answer from here — as of August 30, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with LX-7101, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account